TP53 and gastric cancer: In bioinformatic analyses, ACAT1’s inhibitory effect on gastric cancer may be related to the Adipocytokine Signaling Pathway, the Ppar Signaling Pathway, propanoate metabolism, and the P53 Signaling Pathway.